The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

CVS Health (CVS) closed the most recent trading day at $61.96, moving -2.12% from the previous trading session. This change lagged the S&P 500's 0.01% loss on the day. Elsewhere, the Dow lost 0.32%, ...

That shows the power of CVS’ market saturation; it pushed Hyrimoz through every arm of its business. CVS said the list price of Hyrimoz is 81% cheaper than brand-name Humira.

For 2025, Barclays estimates market forecasts include expectations of 110 basis points in Medicare margin expansion, which is on the lower end of CVS’s target range of 100-200 bps.

CVS Health (CVS) closed at $67.58 in the latest trading session, marking a +1.15% move from the prior day. This move outpaced the S&P 500's daily gain of 1.11%. Elsewhere, the Dow gained 1.19% ...

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite ...